NASDAQ:MYOK - Myokardia Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Myokardia Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $66.70 +1.43 (+2.19 %) (As of 12/15/2019 03:14 PM ET) Add Compare Today's Range$65.27Now: $66.70▼$67.0950-Day Range$52.18MA: $60.74▼$67.4352-Week Range$39.01Now: $66.70▼$68.60Volume279,879 shsAverage Volume353,818 shsMarket Capitalization$3.08 billionP/E RatioN/ADividend YieldN/ABeta2.06 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email MyoKardia, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Its lead product candidate is mavacamten, an orally administered small molecule, which is in Phase III clinical trial that is designed to reduce left ventricular contractility to alleviate the functional consequences and symptoms of obstructive hypertrophic cardiomyopathy (HCM) and prevent or reverse HCM progression, as well as in Phase II clinical trial for non-obstructive HCM. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MYOK Previous Symbol CUSIPN/A CIK1552451 Webhttp://www.myokardia.com/ Phone650-741-0900Debt Debt-to-Equity RatioN/A Current Ratio9.63 Quick Ratio9.63Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$33.56 million Price / Sales91.88 Cash FlowN/A Price / Cash FlowN/A Book Value$9.20 per share Price / Book7.25Profitability EPS (Most Recent Fiscal Year)($1.76) Net Income$-67,700,000.00 Net MarginsN/A Return on Equity-30.34% Return on Assets-28.29%Miscellaneous Employees165 Outstanding Shares46,230,000Market Cap$3.08 billion Next Earnings Date2/27/2020 (Estimated) OptionableOptionable Receive MYOK News and Ratings via Email Sign-up to receive the latest news and ratings for MYOK and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:MYOK Rates by TradingView Myokardia (NASDAQ:MYOK) Frequently Asked Questions What is Myokardia's stock symbol? Myokardia trades on the NASDAQ under the ticker symbol "MYOK." How were Myokardia's earnings last quarter? Myokardia Inc (NASDAQ:MYOK) issued its quarterly earnings data on Monday, November, 11th. The biotechnology company reported ($1.34) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.91) by $0.57. View Myokardia's Earnings History. When is Myokardia's next earnings date? Myokardia is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Myokardia. What price target have analysts set for MYOK? 10 analysts have issued twelve-month price objectives for Myokardia's shares. Their forecasts range from $70.00 to $90.00. On average, they anticipate Myokardia's stock price to reach $80.00 in the next twelve months. This suggests a possible upside of 19.9% from the stock's current price. View Analyst Price Targets for Myokardia. What is the consensus analysts' recommendation for Myokardia? 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Myokardia in the last year. There are currently 1 hold rating and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Myokardia. What are Wall Street analysts saying about Myokardia stock? Here are some recent quotes from research analysts about Myokardia stock: 1. According to Zacks Investment Research, "MyoKardia, Inc. is a biopharmaceutical company. The company focuses on discovering, developing, and commercializing therapies for the treatment of serious and neglected rare cardiovascular diseases. Its product candidate consists of MYK-461, a small molecule to reduce excessive cardiac muscle contractility leading to hypertrophic cardiomyopathy, DCM-1, treats heritable dilated cardiomyopathy by restoring normal contractility in the diseased DCM heart, HCM-2, a product candidate to reduce cardiac muscle contractility to normal levels in HCM patients and LUS-1, which is intended to counteract a muscle disruption that results in impaired relaxation of the heart, which are in different clinical trial. MyoKardia, Inc. is headquartered in San Francisco, California. " (8/13/2019) 2. Cantor Fitzgerald analysts commented, ": 12-month price target of $90. MYOK reported earnings this evening and an increased cash balance of ~ $630M after raising capital in 1Q19. We think that the company is well-capitalized to take advantage of its research discovery platform. One key update today was that the MAVERICK study (non-obstructive) has completed enrollment. We expect that this study will be an important catalyst for the company in 4Q19; we still think that current share levels do not reflect credit for non-obstructive. We still see additional pipeline catalysts beyond mavacamten in obstructive in 2H 2019 that keep us very positive on shares at the current level." (5/9/2019) Has Myokardia been receiving favorable news coverage? Press coverage about MYOK stock has trended somewhat negative on Sunday, according to InfoTrie. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Myokardia earned a media sentiment score of -1.9 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Myokardia. Who are some of Myokardia's key competitors? Some companies that are related to Myokardia include GALAPAGOS NV/S (GLPG), Bausch Health Companies (BHC), Teva Pharmaceutical Industries (TEVA), Elanco Animal Health (ELAN), Mylan (MYL), Ono Pharmaceutical (OPHLF), Ionis Pharmaceuticals (IONS), Beigene (BGNE), Jazz Pharmaceuticals (JAZZ), Amarin (AMRN), Catalent (CTLT), Sarepta Therapeutics (SRPT), Perrigo (PRGO), ACADIA Pharmaceuticals (ACAD) and Dr.Reddy's Laboratories (RDY). What other stocks do shareholders of Myokardia own? Based on aggregate information from My MarketBeat watchlists, some companies that other Myokardia investors own include Exelixis (EXEL), CVS Health (CVS), Micron Technology (MU), CA (CA), NVIDIA (NVDA), BlackRock (BLK), Johnson & Johnson (JNJ), Amgen (AMGN), Kratos Defense & Security Solutions (KTOS) and Alibaba Group (BABA). Who are Myokardia's key executives? Myokardia's management team includes the folowing people: Mr. Tassos Anastasios Gianakakos, Pres, CEO & Director (Age 46)Dr. Robert S. McDowell, Chief Scientific Officer (Age 61)Dr. June Lee, Exec. VP & Chief Devel. Officer (Age 53)Dr. Charles J. Homcy, Advisor (Age 71)Dr. Eric J. Topol, Advisor (Age 65) Who are Myokardia's major shareholders? Myokardia's stock is owned by a variety of of institutional and retail investors. Top institutional investors include State Street Corp (2.11%), Orbimed Advisors LLC (1.69%), Pictet Asset Management Ltd. (0.73%), Voya Investment Management LLC (0.52%), Rhenman & Partners Asset Management AB (0.43%) and Castleark Management LLC (0.29%). Company insiders that own Myokardia stock include Anastasios Gianakakos, Jake Bauer, Joseph Lambing, June Lee, Kevin P Starr, Marc Semigran, Sanofi and Taylor C Harris. View Institutional Ownership Trends for Myokardia. Which institutional investors are selling Myokardia stock? MYOK stock was sold by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Rhenman & Partners Asset Management AB, Voya Investment Management LLC, Pictet Asset Management Ltd., Squarepoint Ops LLC, State Street Corp, grace capital and Partner Investment Management L.P.. Company insiders that have sold Myokardia company stock in the last year include Anastasios Gianakakos, Jake Bauer, June Lee, Sanofi and Taylor C Harris. View Insider Buying and Selling for Myokardia. Which institutional investors are buying Myokardia stock? MYOK stock was bought by a variety of institutional investors in the last quarter, including Castleark Management LLC, California Public Employees Retirement System, State of New Jersey Common Pension Fund D, Man Group plc, First Trust Advisors LP, Handelsbanken Fonder AB, Nisa Investment Advisors LLC and NJ State Employees Deferred Compensation Plan. Company insiders that have bought Myokardia stock in the last two years include Anastasios Gianakakos and Sanofi. View Insider Buying and Selling for Myokardia. How do I buy shares of Myokardia? Shares of MYOK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Myokardia's stock price today? One share of MYOK stock can currently be purchased for approximately $66.70. How big of a company is Myokardia? Myokardia has a market capitalization of $3.08 billion and generates $33.56 million in revenue each year. The biotechnology company earns $-67,700,000.00 in net income (profit) each year or ($1.76) on an earnings per share basis. Myokardia employs 165 workers across the globe.View Additional Information About Myokardia. What is Myokardia's official website? The official website for Myokardia is http://www.myokardia.com/. How can I contact Myokardia? Myokardia's mailing address is 333 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-741-0900 or via email at [email protected] MarketBeat Community Rating for Myokardia (NASDAQ MYOK)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 251 (Vote Outperform)Underperform Votes: 242 (Vote Underperform)Total Votes: 493MarketBeat's community ratings are surveys of what our community members think about Myokardia and other stocks. Vote "Outperform" if you believe MYOK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MYOK will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/15/2019 by MarketBeat.com StaffFeatured Article: What are benefits of a growth and income fund?
